Aardvark Therapeutics, Inc. Common Stock
AARDAardvark Therapeutics, Inc. (AARD) is a biotechnology company focused on developing innovative therapies for neurological and neurodegenerative diseases. The company leverages advanced scientific research to target these complex conditions, aiming to create effective treatment options.
Company News
Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and...
Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101 due to serious cardiac safety concerns. The abrupt halt contradicts prior investor assurances about the drug's safety profile, prompting Hagens Berman to investigate potential securities law violations and misleading disc...
Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101, citing serious cardiac safety concerns. The abrupt halt contradicted prior investor assurances about the drug's safety profile, prompting shareholder rights firm Hagens Berman to investigate potential securities law viol...
Aardvark Therapeutics' stock plummeted 56.2% to $5.47 per share on March 2, 2026, after the company announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in healthy volunteers at above-target therapeutic doses. The Portnoy Law Firm has initiated an investigation into possible securities fraud and may file a ...
Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. and FS KKR Capital Corp. The law firm is also issuing a retraction regarding a previous investigation notice about Ambarella, Inc.
